A joint Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. patent details NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.